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Background: Olanzapine use has been reported during pregnancy and breastfeeding, but there are no controlled
clinical trials assessing the safety of olanzapine exposure to infants and fetuses. The purpose of this report was to
review and analyze prospective post-marketing cases of pregnancy and breastfeeding with olanzapine, in order to
guide clinicians and women on the use of olanzapine therapy during pregnancy and/or breastfeeding.
Methods: A worldwide safety database maintained by Eli Lilly and Company was searched for all spontaneous-reported
data regarding olanzapine use during pregnancy and/or breastfeeding. Cases reported prior to pregnancy outcome
were considered to be prospective, and follow-up was pursued after the delivery date to assess outcome.
Results: Outcome data were available for 610 prospectively identified pregnancies during which olanzapine was used.
The majority of women had normal births (66%), although premature births were reported in 9.8% and perinatal
conditions in 8% of the pregnancies. A total of 102 pregnancies reported olanzapine treatment during breastfeeding. In
these infants, the most commonly reported adverse events were somnolence (3.9%), irritability (2%), tremor (2%), and
insomnia (2%), although the majority of pregnancies reported no adverse events (82.3%).
Conclusions: The frequency of fetal outcomes in these prospectively identified pregnancies exposed to olanzapine did
not differ from rates of outcomes reported in the general population. These data may be useful to help guide clinicians
and women decide to continue, or discontinue, olanzapine therapy during pregnancy and/or breastfeeding, but should
be considered within the limitations associated with spontaneously reported data. Women should notify their clinicians
if they become pregnant or intend to become pregnant while being treated with olanzapine. Because of limited
experience in humans, olanzapine should be used in pregnancy only when potential benefit justifies potential risk to the
fetus. Olanzapine should only be considered during breastfeeding when the potential benefit justifies the potential risk
to the infant.
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Women with psychiatric conditions may become pregnant,
and motherhood is common in such women: in one
sample, 63% of women with psychotic disorders were
mothers [1]. Women with psychotic disorders who
are pregnant or breastfeeding are often treated with
antipsychotics [2]. Due to ethical constraints restricting in-
clusion of pregnant and breastfeeding women in clinical
trials, there is a paucity of data available on the use of anti-
psychotic drugs in this population. The current literature
on antipsychotic use during pregnancy and breastfeeding* Correspondence: ebrunner@lilly.com
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reproduction in any medium, provided the orstems from case reports and large, uncontrolled reports of
prospective and retrospective data [3,4], making it difficult
to draw conclusions concerning the safety of these medica-
tions for the mother and child. Adverse outcomes during
pregnancy, delivery, post-natal care as well as birth defects,
and perinatal complications have been reported in patients
treated with antipsychotics [4].
Women with schizophrenia and bipolar disorder have a
greater likelihood of complications, including placental
abnormalities; hemorrhaging; fetal distress; congenital
anomalies, such as cardiovascular defects; and neonatal
complications [5]. Additionally, cessation of antipsychotic
treatment for women with psychotic disorders may
increase the risk of relapse, which in turn could lead tol Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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adverse events [4]. Therefore, clinicians and women must
carefully weigh the benefits and the risks of remaining on
or terminating antipsychotic treatment.
Olanzapine has been shown to be effective for treating
the symptoms of schizophrenia and bipolar disorder in
adults and schizophrenia and acute manic or mixed
episodes associated with bipolar disorder in adolescents
[6-10]. There have been reports about the safety of
olanzapine in the fetus and infant, with some cases
reporting normal births without complications and others
reporting adverse outcomes, such as differences in birth
weight [11] and neural development [2]. In preclinical trials,
prenatal treatment with olanzapine did not disrupt spatial
memory and short-term memory in rats, whereas other
antipsychotics did [12].
In the absence of adequate and well-controlled clinical
trials, spontaneous post-marketing adverse event data pro-
vides information on the safety of treatment with anti-
psychotic medications during pregnancy and breastfeeding.
Spontaneous post-marketing data typically involve a much
greater number of exposures to a much broader population
of patients compared with data from clinical trials. This is
particularly true in this population (women who are
pregnant or breastfeeding), since pregnant women are
excluded from clinical trials. However, this should be
considered within the limitations associated with spontan-
eously reported data, which may sometimes under repre-
sent the true incidence of events, as not all patients or
clinicians report pregnancies and their outcomes to Eli Lilly
and Company. Here we present prospectively collected data
from Eli Lilly and Company’s safety database including
spontaneous reports, clinical trial cases, and post-marketing
observational study reports, regarding the use of olanzapine
during pregnancy and/or breastfeeding.
Methods
Database
Eli Lilly and Company (Lilly) has maintained a world-
wide safety database of all adverse events reported to
Lilly relative to treatment with products marketed by
Lilly since 1983. This database consists of all spontan-
eous adverse events—regardless of severity—reported in
patients treated with olanzapine (including data from
published literature and regulatory agency reports),
and serious adverse event reports from clinical trials
and post-marketing studies. Additionally, the database
contains reports of olanzapine use during pregnancy
and/or breastfeeding, even if no adverse outcome was
reported. Cases are entered into the database regardless of
the reporter type (e.g., healthcare provider, patient),
concomitant medications or medical co-morbidities,
or consideration of the potential relationship between
olanzapine treatment and the outcome. In the cases thatwere reported from clinical trials (the minority of cases),
the institutional review boards approved the protocols for
all these trials and studies were conducted in accordance
with ethical principles of Good Clinical Practice and the
Declaration of Helsinki and its guidelines. This review was
a retrospective analysis of data from the Lilly Safety
Database (the Lilly Safety Database is the global database
application used for the collection, storage, and reporting
of adverse events to regulatory agencies, investigators,
and internal departments). The information that was
prospectively collected is derived from spontaneously
reported pregnancies. In all cases, the initial contact
to Lilly is made by the reporter. Lilly then sends a letter and
a questionnaire requesting additional information. When
information is not provided directly by the patient, Lilly
also requests the patient’s consent for release of medical
information. Authorizations were not possible to obtain
from patients who did not provide any follow-up informa-
tion. Since the population in this review consists of preg-
nancies with prospective follow-up data, subjects without
any follow-up information were not included in this review.
Ethical or Institutional Review Board approval is not
mandated (as opposed to prospectively collected data
for study purposes from clinical trial participants).
Reports of olanzapine exposure during pregnancy were
categorized based on when the report was received relative
to the report of the pregnancy outcome. For prospective
pregnancy cases (in which the olanzapine exposure was
reported before the report of the pregnancy outcome),
each reporter was contacted after the expected delivery
date for outcomes. Retrospective reports were not used to
calculate frequency of pregnancy outcomes for comparison
with the general population, since not all olanzapine
exposures resulting in pregnancy, nor all outcomes of
pregnancy, are reported.
Definitions
An event represents a clinical sign, symptom, or syndrome
reported for a single reported outcome; therefore, more
than one event may occur in a patient or the patient’s
child. Normal birth was defined as birth between 37 and
42 weeks of gestation, or at an undefined gestation
time with no reported abnormalities; premature birth
was defined as birth before 37 weeks of gestation;
and post-term birth was defined as birth after 42 weeks
of gestation.
As per the World Health Organization (WHO),
‘Congenital anomalies, also known as birth defects, are
structural or functional abnormalities, including metabolic
disorders, which are present from birth. Congenital anom-
alies are a diverse group of disorders of prenatal origin
which can be caused by single gene defects, chromosomal
disorders, multifactorial inheritance, environmental
teratogens and micronutrient deficiencies [13].
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occurring within 7 days of birth, and post-perinatal condi-
tion was defined as an adverse event occurring any time
after 7 days post-birth. Elective termination was defined as
a planned abortion with no anomalies; therapeutic abortion
as a planned abortion due to medical reasons; and a spon-
taneous abortion as a failure of embryonic development,
fetal death in utero, or expulsion of any of all or part of the
product of conception before the 20th week of gestation or
a fetal weight of <500 grams. Stillbirth was defined as death
of the fetus at any time after the 20th week of gestation,
with no breathing or other evidence of life after birth, and
may also be referred to as intrauterine death. Neonates
born at 37 to 42 weeks’ gestation, or at an unspecified
gestation, with no reported adverse events were considered
full term. Neonates born before 37 weeks’ gestation were
considered premature, while neonates born after 42 weeks
of gestation were considered post-term.
After birth, neonates were classified as normal if there
were no issues noted. A congenital anomaly was defined
as a tissue malformation seen in a neonate, born at 37 to
42 weeks’ gestation, or at an unspecified gestation, with
a congenital anomaly noted at birth, or a report of a
therapeutic abortion due to congenital anomalies in the
fetus. A perinatal condition was defined as an adverse
event (not considered to be a congenital anomaly) that
occurred within 7 days of birth in neonates born at 37
to 42 weeks’ gestation or at an unspecified gestation. A
post-perinatal condition was defined as an adverse event
(not considered to be a congenital anomaly) that occurred
after 7 days of birth in neonates born at 37 to 42 weeks’
gestation or at an unspecified gestation age.
Analysis
The safety database was searched for all reports of
pregnancy and breastfeeding in temporal association
with treatment with olanzapine occurring from first
(10 September 1986) human dose in a clinical trial
through 31 December 2010. Pregnancy outcomes, as well
as trimester of olanzapine exposure, were analyzed through
31 December 2010. Qualitative comparisons were made
between this dataset and historic reports from the general
population on rates of outcomes of and during pregnancy,
delivery, and fetal outcomes (see Table 1) [14-24].
Results
Pregnancy outcomes
Through 31 December 2010, there were 610 prospectively
identified pregnancies with an available outcome reported
and included in this analysis. In addition, 73 cases reported
an elective termination without a fetal anomaly, and were
not included in the analysis. Maternal oral olanzapine dose
was reported in 535 of 610 (87.7%) pregnancies and oral
olanzapine doses ranged from 0.6 mg/day to 35.0 mg/day,with a mean dose of 10.3 mg/day. Intramuscular injections
were reported in several cases (<1%) with reported
maternal doses within the labeled dose range.
Of the 610 prospectively identified pregnancies
exposed to olanzapine with an available outcome, there
were 401 (66%) normal births, 60 (9.8%) premature births,
57 (9.3%) spontaneous abortions, 49 (8%) perinatal condi-
tions, 27 (4.4%) congenital anomalies, and 16 (2.6%) other
(post-perinatal condition, ectopic pregnancy, post-term
birth, and stillbirth). There did not appear to be an in-
creased risk of spontaneous abortion, ectopic pregnancy,
stillbirth, premature or post-term birth, or congenital
anomalies in pregnant women treated with olanzapine
compared with historic control rates in the general popu-
lation (Table 1). Given the well-known limitations of the
data under review, the findings need to be interpreted
with caution.
The timing of exposure to olanzapine during pregnancy
was reported in 594 (97.4%) of the prospectively reported
cases. Of these, the majority reported olanzapine exposure
either during all three trimesters 263 (44.3%) or in
the first trimester only 187 (31.5%). Approximately
47.1% (189/401) of women experiencing normal births
were exposed to olanzapine during all three trimesters.
The majority of women who experienced spontaneous
abortions were exposed to olanzapine during the first
trimester only (50/57, 87.7%). Approximately half of
the women who experienced premature (27/60, 45%)
or post-mature births (3/5, 60%) were treated with
olanzapine throughout pregnancy. Among women
who experienced perinatal conditions, 63.3% (31/49) were
exposed to olanzapine for all three trimesters and
6.1% (3/49) were exposed to olanzapine during the
third trimester only (Table 2). Forty-three percent of
women reported continuation of treatment with olanzapine
during all three trimesters of their pregnancy (Table 2). In
patients who continued olanzapine treatment throughout
all three trimesters, 71.9% had normal births. Exposure
during only the first trimester of pregnancy was reported in
30.7% of pregnancies.
Of the prospectively identified pregnancies with an
available reported outcome, 27 (4.4%) reported congenital
anomalies; this risk did not appear to be greater in the
population being treated with olanzapine compared with
the general population (Table 1).
Breastfeeding
In women being treated with olanzapine while breast-
feeding, from spontaneous reports, clinical trial cases, and
post-marketing observational study reports, (N=102), 62
pregnancies included olanzapine dose information: doses
ranged from 2.5 to 20.0 mg/day, with a mean dose of 7.4
mg/day. All reported an oral dose form. Duration of
olanzapine exposure during breastfeeding was reported in
Table 1 Fetal outcomes in prospectively identified olanzapine-exposed pregnancies, compared to rates in the general
population†
Fetal outcome Outcome reported (%) (N=610) Historic control rate in general population (%)
Spontaneous abortion 57 (9.3%)g 10% to 20% [19,20]
Ectopic pregnancy 3 (0.5%) 1.3% to 2.1% [21-23]
Normal birtha 401 (65.7%) 61% to 64% [24]
Prematureb 60 (9.8%) 12.8% [25]
Post-termc 5 (0.8%) 5.6% [25]
Stillbirth 5 (0.8%)h 0.5% to 1.1%i [26,27]
Congenital anomalyd 27 (4.4%) 3.0% to 5.0% [28,29]
Perinatal conditione 49 (8.0%) j
Post-perinatal conditionf 3 (0.5%) j
a Includes neonates born at 37–42 weeks’ gestation, or at an unspecified gestation.
b Includes neonates born <37 weeks’ gestation or reported as “premature.”
c Includes neonates born >42 weeks or reported as “post-term.”
d Includes neonates born at 37–42 weeks’ gestation or at an unspecified gestation with a congenital abnormality (resulting from abnormal tissue formation) at
birth, and reports of therapeutic abortions due to congenital abnormalities in the fetus.
e Includes neonates born at 37–42 weeks’ gestation or at an unspecified gestation with adverse event ≤7 days of birth.
f Includes neonates born at 37–42 weeks’ gestation or at an unspecified gestation with an adverse event >7 days after birth.
g Includes one report of a congenital anomaly in a 13-week aborted fetus.
h Includes one report of a normal fetus who died when the mother committed suicide at 8 months’ gestation.
i Indicates range when stratified by race/ethnicity.
j Due to the specific definitions (gestation and adverse events in a timeframe after birth), historical population rates are not available.
† Clinical trial and spontaneous reports from the Lilly worldwide safety database (First human dose through 31 December 2010).
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with a mean exposure of 74 days, and a median exposure
of 30 days. In a study in lactating, healthy women taking
oral olanzapine, olanzapine was excreted in breast
milk. Mean infant exposure (mg/kg) at steady state
was estimated to be 1.8% of the maternal olanzapine dose
(mg/kg) [25]. In the olanzapine safety database, there were
no adverse events reported in the neonate/infant in the
majority (82.3%) of pregnancies that reported breastfeeding
during olanzapine treatment. A total of 15.6% of the
pregnancies reported an adverse event in the neonate
or infant in temporal association with breastfeeding.
The most commonly reported adverse events included
somnolence (3.9%), irritability (2%), tremor (2%), and
insomnia (2%). Outcomes of these events noted in the
neonate/infant were reported as recovered/recovering in
40% of the events, as not recovered in 24% of the events,
and as unknown in 36% of the events.
Discussion
Through 31 December 2010, it is estimated that more
than 33 million patients were treated with olanzapine.
Based on the analysis of prospectively reported preg-
nancy where there was an outcome available, 66% of
the outcomes of women treated with olanzapine at
any time during pregnancy were normal. This rate of
normal birth outcomes is comparable to that of the
general population, which ranges from 61% to 64%
[19]. Premature births (9.8%) and spontaneous abortion
(9.3%) rates in this dataset were comparable to those of thegeneral population (12.8% [20] and 10% to 20% [14,15],
respectively).
Prospective reports are subject to fewer reporting
biases compared with retrospective reports [26]. Women
whose children have major birth defects (abnormality
that can affect the structure or function of an organ)
are more likely to report the outcome, compared with
women who have healthy babies [27]. Prospectively
collected information provides more details about a
case and helps to provide a risk estimate [28], whereas
retrospective reports may be susceptible to systematic recall
bias and underestimation of exposure to maternal psychi-
atric illness and non-psychotropic agents [29], and cannot
be used in the calculation of outcome rates [30]. In
addition, prospective cohorts are able to include specific
variables, and the data can be collected with more reliability
and accuracy [31], thus providing an opportunity to obtain
follow-up information, and a more accurate ascertainment
of exposure during pregnancy and in the perinatal period.
Therefore, in this population, prospective reports were
used to calculate frequency of pregnancy outcomes for
comparison to the general population.
The risk of unfavorable outcomes in neonates and
infants whose mothers were treated with olanzapine
during pregnancy in this dataset did not appear to differ
from that of the general population. This information is
complementary to the findings of a previous prospective
study of pregnancy outcomes in patients treated with
atypical antipsychotics. The defects in the infant of the
olanzapine-treated patient included the midline defects
Table 2 Trimester of olanzapine exposure in prospectively identified pregnancies by outcome from Lilly Worldwide
Safety Database†
Outcomes reported by trimester(s) of exposure to Olanzapine (n)
Pregnancy outcome 1st only 2nd only 3rd only 1st & 2nd 1 & 3rd 2nd & 3rd All Unknown Total
Normal birtha 109 14 18 37 7 21 189 6 401
Full-term 96 12 17 33 6 20 169 4 357
Unknown gestation 13 2 1 4 1 1 20 2 44
Spontaneous abortiona 50 1 0 4 0 0 0 2 57g
Ectopic pregnancy 3 0 0 0 0 0 0 0 3
Prematureb 11 1 2 4 1 11 27 3 60
Normal 7 1 0 3 1 8 18 3 41
Congenital anomaly 2 0 0 0 0 0 2 0 4
Perinatal condition 2 0 2 1 0 3 7 0 15
Post-termc 0 0 2 0 0 0 3 0 5
Normal 0 0 2 0 0 0 1 0 3
Perinatal condition 0 0 0 0 0 0 2 0 2
Stillbirth 0 0 0 0 0 1 4 0 5h
Congenital anomalyd 3 1 2 4 0 7 8 2 27
Full-term 2 1 2 1 0 4 8 0 18
Unknown gestation 0 0 0 2 0 3 0 2 7
Therapeutic abortion 1 0 0 1 0 0 0 0 2
Perinatal conditione 9 0 3 2 0 1 31 3 49
Full-term 8 0 3 1 0 1 28 3 44
Unknown gestation 1 0 0 1 0 0 3 0 5
Post-perinatal conditionf 2 0 0 0 0 0 1 0 3
Full-term 2 0 0 0 0 0 1 0 3
Totals 187 17 27 51 8 41 263 16 610
a Includes neonates born at 37–42 weeks’ gestation, or at an unspecified gestation.
b Includes neonates born <37 weeks’ gestation or reported as “premature.”
c Includes neonates born >42 weeks’ or reported as “post-term.”
d Includes neonates born at 37–42 weeks’ gestation or at an unspecified gestation with a congenital abnormality (resulting from abnormal tissue formation) at
birth, and reports of therapeutic abortions due to congenital abnormalities in the fetus.
e Includes neonates born at 37–42 weeks’ gestation or at an unspecified gestation with an adverse event ≤7 days after birth.
f Includes neonates born at 37–42 weeks’ gestation or at an unspecified gestation with an adverse event >7 days after birth.
g Includes one report of a congenital anomaly in a 13-week aborted fetus.
h Includes one normal fetus who died when the mother committed suicide at 8 months’ gestation.
† First Human Dose through 31 December 2010 (Data on file).
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these events occurred in one child of an olanzapine-treated
mother, compared with none in the other treatment groups
[2]. Given the well-known limitations of the data under
review, the findings need to be interpreted with caution.
Other congenital defects, including meningocele/
ankyloblepharon [32], hip dysplasia [33], acheiria [34], and
atrioventricular canal defect/unilateral clubfoot [35], have
been reported in infants exposed to olanzapine in utero.
In a postmarketing safety database assessment of 68
prospective pregnancies, spontaneously reported with a
known outcome in women who received risperidone
[3], 37 pregnancies reported a normal outcome. Organ
malformations were reported in 3.8% of the reports andspontaneous abortions in 16.9% of the reports. The
denominator used was subtracting the number of induced
abortions (predominantly undertaken for nonmedical
reasons) from the total 68 reports. In utero exposure to
risperidone does not appear to increase the risk of spon-
taneous abortions, structural malformations, and fetal
teratogenic risk above that of the general population.
In a prospective, controlled cohort study of 215 preg-
nancies in women exposed to haloperidol or penfluridol
[36], rates of major abnormalities were compared to a
control group of pregnancies (N=631) exposed to
non-teratogenic agents reported to a European counseling
center. Compared to the controlled group, the women
treated with antipsychotics were older; and a significantly
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No differences were noted in the number of previous
miscarriages, number of pregnancies, history of elective
terminations, or gestational age at first contact. No differ-
ences were observed between the antipsychotic-exposed
group and the control group in the rates of major
malformations (3.4% vs. 3.8% respectively) or in the rates
of major malformations in live births with first tri-
mester exposure (3.1% vs. 3.8% respectively). There
were statistically significant differences observed between
the antipsychotic-exposed group and the control group in
the rates of delivery (81.9% vs. 90.3% respectively), elective
termination of pregnancy (8.8% vs. 3.8% respectively),
preterm birth (13.9% vs. 6.9% respectively), Cesarean
section (25.5% vs. 16.3% respectively), and in the
median gestational age [interquartile range] at delivery
(40 [38-40] vs. 40 [39-41] weeks respectively), median
birthweight [interquartile range] (3155 [2800–3500]
vs. 3370 [3030–3700] g respectively), and median birth-
weight [interquartile range] of full-term infants (3250
[3000–3590] vs. 3415 [3140–3750] g respectively).
In this dataset, 66% of births were classified as normal
births; premature births occurred in 9.8% of pregnancies.
This is not consistent with the findings of Newham et al.
[37], who found higher rates of premature births in
infants whose mothers were treated with typical antipsy-
chotics compared with a non-medicated reference group,
although there was no significant difference between the
atypical antipsychotic and the reference groups. This
analysis, as ours, did not control for concomitant
mediations or other potential confounders, which may
have potentially affected gestational age.
Although this analysis did not examine birth weight,
previous studies have found higher rates of low birth
weight (31%) and neonatal intensive care unit admis-
sion (31%) reported in neonates whose mothers were
treated with olanzapine during pregnancy compared
with neonates of mothers who were treated with
other atypical antipsychotics [11], although the differ-
ences were not statistically significant. Another study
found that infants born to mothers who were treated
with olanzapine or clozapine during pregnancy had
significantly higher birth weights compared with
infants of mothers who were treated with typical anti-
psychotics [37].
One study examining placental passage (defined as the
ratio of umbilical cord to maternal plasma concentration)
of antipsychotics found that olanzapine concentrations
in the placenta were 72% of the mother’s, which was
significantly greater compared with concentrations of
haloperidol, quetiapine, and risperidone [11]. However,
another study reported the rate of placental passage
of olanzapine to be much lower (17%) [38]. Potential
fetal exposure to olanzapine should be taken intoconsideration when weighing the benefits and risks of
remaining on olanzapine therapy.
Infant exposure to olanzapine via breast milk of
olanzapine-treated mothers was lower than exposure in
utero. Adverse events were reported in 15.6% of infants
who were exposed to olanzapine through breast milk,
and the most common events included somnolence,
irritability, tremor, and insomnia. This differs from
several studies of olanzapine in which either no adverse
events were noted [39-43], or the types of adverse events
(e.g., respiratory difficulties and hypotonia) were different
[44]. The safety profile of olanzapine is based on
exposures to the drug in adults and adolescents, the
safety profile of exposure through uterus, during early
and late developmental stages or via breast milk is
likely to differ. Gilad et al. [44] found that the rate of
adverse events in olanzapine-exposed breastfed infants
were not statistically significantly different from infants
not exposed to olanzapine.
The information reviewed in the current paper was
voluntarily reported by (or on behalf of ) the patient
(spontaneous adverse event reports). There are several,
well-known limitations to spontaneously reported data.
Spontaneous reporting of adverse events may be highly
variable [45]: clinicians may be less likely to report
adverse events that are not serious or have been seen in
the general population; this may skew the data toward
more serious adverse events. Similarly, the information
collected may lack details in particular key information,
such as concurrent treatments, relevant medical history,
and long-term follow-up of infant developmental out-
comes. The data reported here included all reported
cases regardless of concomitant medications, relevant
medical co-morbidities, and potential causal relationship
to olanzapine exposure. Since this is not a clinical trial,
data are not collected like they typically are in a clinical
trial or in a prospective observational study where there
is a defined protocol. The follow-up rate cannot be
calculated from spontaneously reported data as there is
no pre-defined duration of follow-up for individual
patient reports. Moreover, due to the nature of spontaneous
reporting, and given the process of soliciting and obtaining
follow-up information, a follow-up rate often does not
provide an informative assessment of the completeness
and accuracy of the follow-up. Although follow-up infor-
mation may have been received, often the most relevant
follow-up is the outcome of pregnancy/breastfeeding,
which may not always be available. In addition, it is not
possible to confirm the exact trimester in which the
patients were exposed to olanzapine from spontaneously
reported data. In summary, spontaneous data alone are
not adequate to make definitive conclusions regarding
the potential risk of adverse events following exposure
to olanzapine.
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System (AERS), the Food and Drug Administration’s (FDA)
computerized information database designed to monitor
for new adverse events and support post-marketing safety
surveillance for approved drugs, various major regulatory
agencies recently updated the prescribing information label
language of all antipsychotics regarding use during
pregnancy, informing of the potential risk of abnormal
muscle movements (extrapyramidal signs) and/or with-
drawal symptoms in neonates whose mothers were
treated with antipsychotics during the third trimester
of pregnancy [46]. It is important to assess the risks
and benefits of treating women who are pregnant or
breastfeeding with antipsychotics, and weigh these against
possible risks of anomalies and developmental problems
to the fetus and infant.
Conclusions
There are no controlled studies for the use of olanzapine
therapy in pregnant women or in women who are
breastfeeding. Given the well-known limitations of data
under review, the findings need to be interpreted with
caution. The relative risks and benefits of olanzapine
treatment during pregnancy and/or breastfeeding should
be carefully weighed by the clinician and the patient on
a case-by-case basis. Because of limited experience in
humans, olanzapine should be used in pregnancy only
when potential benefit justifies potential risk to the fetus
[25]. Olanzapine should only be considered during
breastfeeding when the potential benefit justifies the
potential risk to the infant. Women should be advised to
notify their clinician if they become pregnant or intend
to become pregnant during treatment with olanzapine.
Presently, data are not sufficient to make definitive con-
clusions regarding the safety of olanzapine therapy during
pregnancy and/or breastfeeding. However, acknowledging
the limitations of the existing data, our review found that
the frequency of fetal outcomes in prospectively identified
pregnancies exposed to olanzapine did not differ from
rates of outcomes reported in the general population.
In the absence of data from clinical trials, the current
analysis of post-marketing data attempts to provide greater
information about the safety of olanzapine exposure during
pregnancy and/or breastfeeding.
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